[go: up one dir, main page]

ECSP10010555A - Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona - Google Patents

Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona

Info

Publication number
ECSP10010555A
ECSP10010555A EC2010010555A ECSP10010555A ECSP10010555A EC SP10010555 A ECSP10010555 A EC SP10010555A EC 2010010555 A EC2010010555 A EC 2010010555A EC SP10010555 A ECSP10010555 A EC SP10010555A EC SP10010555 A ECSP10010555 A EC SP10010555A
Authority
EC
Ecuador
Prior art keywords
quinolin
piperazin
fluoro
amino
methyl
Prior art date
Application number
EC2010010555A
Other languages
English (en)
Inventor
Danielle Giron
Frank Stowasser
Walter Hammerschmidt
Philippe Piechon
Johanne Polasek
Andreas Schreiner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40622140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010555(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP10010555A publication Critical patent/ECSP10010555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formas cristalinas o polimorfos de las sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1H-bencimidazol-2-il]-quinolin-2(1H)-ona, asi como metodos para la elaboracion de las mismas, composiciones farmaceuticas que comprenden las mismas, y metodos de tratamiento utilizando las mismas.
EC2010010555A 2008-03-19 2010-10-19 Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona ECSP10010555A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3774608P 2008-03-19 2008-03-19

Publications (1)

Publication Number Publication Date
ECSP10010555A true ECSP10010555A (es) 2010-11-30

Family

ID=40622140

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010555A ECSP10010555A (es) 2008-03-19 2010-10-19 Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona

Country Status (24)

Country Link
US (1) US8563556B2 (es)
EP (1) EP2257544B1 (es)
JP (1) JP2011515370A (es)
KR (1) KR20100137517A (es)
CN (1) CN101970425B (es)
AR (1) AR070924A1 (es)
AU (1) AU2009227003B2 (es)
BR (1) BRPI0909762A2 (es)
CA (1) CA2718076A1 (es)
CL (1) CL2009000651A1 (es)
CO (1) CO6321253A2 (es)
EC (1) ECSP10010555A (es)
IL (1) IL208020A0 (es)
MA (1) MA32230B1 (es)
MX (1) MX2010010152A (es)
MY (1) MY150554A (es)
NZ (2) NZ587829A (es)
PE (1) PE20091628A1 (es)
PH (2) PH12012502569A1 (es)
RU (1) RU2497820C2 (es)
SG (1) SG188919A1 (es)
TW (1) TWI426072B (es)
WO (1) WO2009115562A2 (es)
ZA (1) ZA201006263B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona
NZ602807A (en) 2010-04-16 2014-02-28 Novartis Ag 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
DK2558095T3 (en) 2010-04-16 2019-01-14 Novartis Ag ORGANIC RELATIONSHIP FOR USE IN TREATMENT OF DELIVERY CANCER
AR081776A1 (es) * 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
MA34966B1 (fr) 2011-03-17 2014-03-01 Novartis Ag Fgfr et ses ligands utilisés comme biomarqueurs du cancer du sein chez des sujets rh positifs
KR20140023358A (ko) 2011-05-19 2014-02-26 노파르티스 아게 선양 낭성 암종의 치료에 사용하기 위한 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1h-벤즈이미다졸-2-일]-1h-퀴놀린-2-온
US20140221389A1 (en) 2011-09-15 2014-08-07 Novartis Ag Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
WO2013116293A1 (en) 2012-01-31 2013-08-08 Novartis Ag Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
KR20150036014A (ko) 2012-07-11 2015-04-07 노파르티스 아게 위장 기질 종양을 치료하는 방법
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
RS59853B1 (sr) 2014-03-14 2020-02-28 Novartis Ag Molekuli anti-lag-3 antitela i njihove upotrebe
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
KR20170129802A (ko) 2015-03-10 2017-11-27 아두로 바이오테크, 인코포레이티드 ＂인터페론 유전자의 자극인자＂-의존적 신호전달을 활성화하는 조성물 및 방법
SI3317301T1 (sl) 2015-07-29 2021-10-29 Novartis Ag Kombinirane terapije, ki obsegajo molekule protitelesa na LAG-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
EP3370768B9 (en) 2015-11-03 2022-03-16 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386736T1 (de) * 2000-09-11 2008-03-15 Novartis Vaccines & Diagnostic Verfahren zur herstellung von benzimidazol-2-yl - chinolinonderivaten
WO2004018419A2 (en) * 2002-08-23 2004-03-04 Chiron Corporation Benzimidazole quinolinones and uses thereof
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
CN100377709C (zh) * 2002-11-13 2008-04-02 希龙公司 受体酪氨酸激酶抑制剂的制药用途及相关检测方法
BR0316229A (pt) * 2002-11-13 2005-10-04 Chiron Corp Métodos de tratamento de câncer e métodos relacionados
AU2004288709B2 (en) * 2003-11-07 2011-01-06 Novartis Vaccines And Diagnostics, Inc. Methods for synthesizing quinolinone compounds
WO2005082340A2 (en) * 2004-02-20 2005-09-09 Chiron Corporation Modulation of inflammatory and metastatic processes
DK1845990T3 (da) * 2005-01-27 2012-01-02 Novartis Vaccines & Diagnostic Behandling af metastaserede tumorer
BRPI0611375A2 (pt) * 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
CA2627544C (en) 2005-11-29 2015-07-07 Novartis Ag Formulations of quinolinones for the treatment of cancer
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
PE20091628A1 (es) 2008-03-19 2009-11-19 Novartis Ag Formas cristalinas y dos formas solvatadas de sales de acido lactico de 4-amino-5-fluoro-3-[5-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]quinolin-2(1h)-ona

Also Published As

Publication number Publication date
CN101970425A (zh) 2011-02-09
PH12012502569A1 (en) 2015-09-21
PH12012502568A1 (en) 2014-10-27
MY150554A (en) 2014-01-30
HK1147492A1 (en) 2011-08-12
WO2009115562A2 (en) 2009-09-24
US20110021536A1 (en) 2011-01-27
CO6321253A2 (es) 2011-09-20
CL2009000651A1 (es) 2010-07-19
RU2010142396A (ru) 2012-04-27
PE20091628A1 (es) 2009-11-19
IL208020A0 (en) 2010-12-30
US8563556B2 (en) 2013-10-22
EP2257544B1 (en) 2014-12-03
NZ587829A (en) 2012-08-31
CN101970425B (zh) 2014-04-16
MA32230B1 (fr) 2011-04-01
CA2718076A1 (en) 2009-09-24
BRPI0909762A2 (pt) 2018-04-03
ZA201006263B (en) 2011-05-25
AR070924A1 (es) 2010-05-12
AU2009227003A1 (en) 2009-09-24
EP2257544A2 (en) 2010-12-08
WO2009115562A3 (en) 2009-11-26
JP2011515370A (ja) 2011-05-19
KR20100137517A (ko) 2010-12-30
TW201000463A (en) 2010-01-01
AU2009227003B2 (en) 2013-03-14
SG188919A1 (en) 2013-04-30
RU2497820C2 (ru) 2013-11-10
MX2010010152A (es) 2010-10-25
TWI426072B (zh) 2014-02-11
NZ600887A (en) 2013-10-25

Similar Documents

Publication Publication Date Title
ECSP10010555A (es) Formas cristalinas y dos formas solvatadas de sales de acido lactico de la 4-amino-5-fluoro-3-[5-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-quinolin-2(1h)-ona
CL2015003442A1 (es) Derivados heterociclicos
DOP2015000304A (es) Inhibidores cristalinos de bromodominios
ECSP11011011A (es) Derivados de acido 1-amino-2-ciclobutiletilborónico
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
DOP2012000257A (es) Derivados del acido 1-amino-2-ciclopropiletilboronico
CR20110230A (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
NI201100063A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38.
UY34545A (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios.
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
CR20160222U (es) Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
MX2012004311A (es) Derivados de ciclohexano spiro condensados como inhibidores de lipasa sensible a hormonas (hsl) utiles en el tratamiento de diabetes.
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
BR112012031981A2 (pt) composição aquosa de ingrediente ativo, processo, uso, método para controlar fungos fitopatogênicos e semente
UY33549A (es) Quinolil aminas como agentes inhibidores de las quinasas
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
UY34070A (es) Método y composición para tratamiento de semillas.
CR11368A (es) Forma cristalina 1 de 2- ( (r)-2-metilpirrolidin-2-il) -1h-benzimidazol-4-carboxamida
ECSP099736A (es) Aspartato de acido 1-ciclopropil-6-fluoro-7-(8-metoxiimino-2,6-diaza-espiro[3.4]oct-6-il)-4-oxo-1,4-dihidro-[1,8]naftiridin-3-carboxilico, metodo para preparar el mismo y composicion farmaceutica antimicrobiana que comprende el mismo
AR061299A1 (es) Sales de succionato de 6-metoxi -8- [4- (1-(5- fluor) -quinolin -8-il-piperidin-4-il) -piperazin-1-il] -quinolina y formas cristalinas de las mismas